Full-Time

Programme Lead for Experimental Medicine

Research Infrastructure

Posted on 10/6/2025

LGC Group

LGC Group

1,001-5,000 employees

Sells oligos, probes, primers, viral materials

No salary listed

Feltham, UK

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • A PhD degree (or equivalent) in biomedical or health sciences research (or significant equivalent sector experience)
  • Significant relevant experience of managing research funding in a clinical, academic, industrial, funding agency or charity setting
  • Experience of line management, staff development and planning and monitoring of workloads
  • Excellent project planning and management skills; able to prioritise and manage multiple tasks, working to challenging targets and deadlines
  • The ability to demonstrate an understanding in the strategic issues in health and care research funding and policy, especially within experimental medicine
  • Strategic thinker able to interpret complex information while having a clear view of the “big picture”
  • The ability to employ creative approaches to effectively communicate complex information to individuals and groups from a range of different backgrounds and different seniority levels
  • Committed team player with an ability to build effective working relationships
Responsibilities
  • Lead the delivery and strategic development of the experimental medicine research infrastructure portfolio: + Portfolio development: Develop and maintain expert knowledge of the funded portfolio in order to identify gaps or opportunities for greater impact and to build robust cases for new activities. + Strategic direction for existing funding schemes: Oversee the delivery of scheme reviews and evaluations for your portfolio to develop recommendations for the next funding calls. + Working across the health and care research landscape: Represent the schemes and portfolio in discussions with colleagues from DHSC, NIHR and beyond to ensure synergies are identified and can be capitalised on. Contribute to activities to raise the visibility of the awards within academic, clinical, public and government fora. + Commissioning of research: Provide management oversight of the delivery of new funding competitions, development of application guidance notes, the organisation of international panel meetings, the production of minutes and provision of feedback to applicants. + Development of new funding calls: Respond to ad hoc requests from DHSC/NIHR to develop and deliver new priority funding calls, mobilising resources to develop an appropriate assessment mechanism and suitable monitoring processes. + Contract management and annual reporting: Support the team to process contractual requests/changes required during the lifetime of an award and requests for information (e.g. Parliamentary Questions, FOI requests or briefings for ministers). Monitor award progress through an annual reporting process and together with the Assistant Director, sign off on award holder feedback and monitor risk management.
  • },
Desired Qualifications
  • Understanding of research impact and how monitor and measure it

LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Simplify Jobs

Simplify's Take

What believers are saying

  • ChromaDex acquisition February 2026 adds 3,000 phytochemical standards boosting North America sales.
  • Irish Horseracing Board renews LGC contract through 2027 for equine anti-doping analysis.
  • CAD$100 million Canada synthesis center expands pharma research chemical capacity.

What critics are saying

  • Merck KGaA erodes LGC market share with bundled CRMs at lower prices by Q1 2027.
  • WADA 2026 protocol causes Fordham lab to lose 30% human sports testing to NSF by Q4 2026.
  • USFDA revokes Lexington accreditation May 2026, forfeiting $50M horse racing contracts to Eurofins.

What makes LGC Group unique

  • LGC's Informed-Sport certifies 440 products against 250+ banned substances using ISO 17025 labs.
  • Lexington facility expanded November 2016 for equine doping control and US supplements testing.
  • LoGiCal portfolio offers 3,000+ toxicology reference standards since 2012 launch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Company News

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

CHEManager
Sep 12th, 2025
LGC Opens $100 Million Pharma Synthesis Center in Canada

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.

Graham B Jackson (Aust) Pty Ltd
Apr 15th, 2025
Ensuring Precision in Analysis: Graham B Jackson Pty Ltd Supply of LGC Certified Reference Materials

Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.

Health Technology Insights
Apr 4th, 2025
Laboratory Proficiency Testing Market to Reach $2.1 Billion by 2030

For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).

Investors in Healthcare
Jan 10th, 2025
UK: LGC appoints Joydeep Goswami as president and CEO

UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.

INACTIVE